@Bgall and @49parkn, I am not disputing this is a great company. I concur with those sentiments.
The company is on track to make ~$10m EBIT (from $100m gross revenue) this year but has been trading at a valuation of over $500m. A 50x multiple is a little bit excessive for a business of this nature.
It seems more likely that a 10-15x EBITDA multiple would be more appropriate which is consistent with high growth healthcare/ medtech enterprises.
I think it would be naive of us to not expect Ben and Matua to sell down 30% or more of their stock to realise some gains.
IMHO GLTA DYOR
Bell Potter Ratings, page-12
Add VIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
0.009(10.5%) |
Mkt cap ! $54.70M | |||
| Open | High | Low | Value | Volume |
| 8.8¢ | 9.8¢ | 8.8¢ | $21.22K | 225.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | 8.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.5¢ | 18003 | 1 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
9.3¢ |
Change
0.009 ( 8.27 %) |
||||
| Open | High | Low | Volume | ||
| 9.4¢ | 9.6¢ | 9.0¢ | 130230 | ||
| Last updated 15.54pm 05/06/2024 ? | |||||
| VIT (ASX) Chart |